Celltrion, Inc. is a South Korean pharmaceutical company focused on developing and manufacturing therapeutic proteins. With a Risk Rating Score of 30.1, the company is considered high risk. Specializing in biosimilar products that treat various health conditions including breast cancer, rheumatoid arthritis, and colorectal cancer. Celltrion, Inc. emphasizes ESG principles in its operations.